In India, hepatitis C virus (HCV) infection is treated with sofosbuvir in combination with NS5A inhibitor (Daclatasvir, Ledipasvir, or Velpatasvir). A small proportion of them fail to achieve sustained virological response at 12 weeks (SVR12) and need retreatment. Triple-drug combination (Sofosbuvir/Velpatasvir/Voxilaprevir) is one of the options for retreatment. Here we describe a patient with cirrhosis and genotype 3a infection who was successfully treated with a triple-drug combination after relapse with two courses of Sofosbuvir-containing regimens.
Keywords: DAA, Direct-Acting Antiviral drugs; HCV, Hepatitis C virus; hepatitis C retreatment; hepatitis c virus; resistance associated variant; sofosbuvir; velpatasvir; voxilaprevir.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.